US Pharma at Policy Crossroads: Executive Orders, Tariffs, and the Possible Most-Favored-Nation Effect

The US pharmaceutical industry is at critical policy crossroads, facing a wave of changes that could significantly alter pricing structures, market access dynamics, and global strategy. 
In this timely webinar, Simon-Kucher’s pharma experts will examine the implications of recent and proposed Presidential executive orders, the strategic consequences of tariff measures for pharmaceuticals and the potential re-emergence of Most-Favored-Nation (MFN) pricing.

Participants will gain valuable insights into how these developments may disrupt established commercial models - and how companies can proactively adapt to limit potential impact in the evolving US environment.

Key topics include:

• Presidential executive orders and their impact on US drug pricing frameworks
• Tariff risks and their effect on pharmaceutical imports and supply chains
• The return of MFN pricing: Implications for US revenues and global…